All News

Eisai and Acumen Therapeutics will present new data in areas including long-term outcomes, brain delivery strategies, and early-stage Alzheimer disease.

Real-world data from 20 000 patients demonstrate significantly higher adherence rates with Shield blood test vs colonoscopy and stool-based screening methods.

Deep TMS becomes first FDA-cleared brain stimulation therapy for adolescents with treatment-resistant depression and is now available for ages 15-86 for MDD treatment.

TMS: Harvard's Caroline Mitchell, MD, MPH, questions the direction of genitourinary syndrome research priorities and reflects on FDA's removal of HRT warnings.

Study author Daniel Jiang, MD, PhD, discusses data linking hormone therapy to increased autoimmune disease risk in postmenopausal women and clinical implications.

Northwestern University unveils a groundbreaking online tool that helps younger adults understand their 30-year cardiovascular disease risk through percentile rankings.

UK neurodivergent adults report strong views on neurodiversity terminology, emphasizing correct usage and its role in stigma, identity, and communication.

A new study reveals that the Preventive Health Inventory enhances diabetes and hypertension management among veterans without increasing hospitalizations.

In the phase 2 clinical trial, tradipitant, an oral neurokinin-1 receptor antagonist, was dosed twice daily among adults with obesity and treated with semaglutide.

Individuals who have chronic widespread pain showed a 75% increased risk of developing hypertension compared to fellow UK Biobank participants who were pain-free.